Covance Gene Therapies

Gene Therapies

Gene therapies offer a new method of potential treatment, particularly for patients with rare genetic diseases. Whether you’re developing a viral vector-based therapy, such as an adeno-associated virus (AAV) or lentivirus (lenti) product, or applying gene editing technologies such as CRISPR/cas9, you’ll benefit from our Expert Teams’ deep knowledge and experience.

Assess safety, establish proof of concept and feasibility to support IND/IMPD/CTA submissions, and rapidly transition to first-in-human trials

Conduct Phase I, II, and III trials to support BLA/MAA submissions and preparation for post-marketing studies

Conduct real-world evidence studies, fulfill post-marketing commitments and optimize availability to your gene therapy

Preclinical Solutions

  • In vitro & in vivo pharmacology & toxicology (acute & chronic)

  • Bioanalysis/PK: biodistribution, persistence & shedding

  • Biomarker strategy, assay development & testing

  • Regulatory & strategic product development consulting

  • Clinical development preparation & planning

  • BioCMC Testing– safety, identity, strength & purity

  • Commercialization Strategy Development

Clinical Trial Solutions

  • Patient identification & recruitment

  • Protocol modeling & development

  • Project & logistics management and oversight

  • Medical monitoring and specialized training for AEs

  • First in Human/dose range-finding/escalation studies

  • Proof of mechanism/proof of concept (PoM/PoC) trials

  • Lab testing: PK, Biomarkers, Central Labs, Genomics, Specialty Testing and BioCMC

  • Regulatory & strategic product development consulting

  • Long-term follow-up preparation and testing strategy development

Post-Approval Solutions

  • Long-term follow-up studies 

  • Lab Testing

  • Disease and product registries

  • Health economics 

  • Field reimbursement

  • Clinical education

  • Payer and customer relations

  • Differentiation studies

New cell and gene therapy suite

A macro investment in micro science

Cell and gene therapies are incredibly intricate, but they’re making a huge difference in the drug development market and in the lives of patients. Learn all about our $9.2 million investment in cell and gene therapy.


Transforming our services in Early Development

We’ve invested more than $700 million in scientific innovations to advance your nonclinical studies. With our expanded lab space, newest technologies and digitized back offices, the solutions we provide are more innovative than ever.

Two scientists looking at computer screen

Let's Start the Conversation

Want to learn more?

Contact Us